股本结构
单位：万股
| 公告日期 | 2025-11-13 | 2025-11-13 | 2025-08-12 | 2025-08-12 | 2025-05-13 | 2025-03-27 |
|---|---|---|---|---|---|---|
| 证券总股本 | 5633.93 | 5631.18 | 5627.52 | 5618.73 | 5590.06 | 5590.06 |
| 普通股本 | 5633.93 | 5631.18 | 5627.52 | 5618.73 | 5590.06 | 5590.06 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-06 | 2025-09-30 | 2025-08-05 | 2025-06-30 | 2025-03-31 | 2025-03-21 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-13 | 5633.93 | 未披露 | 定期报告 | 2025-11-06 |
| 2025-11-13 | 5631.18 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Issuance of common stock upon the vesting of restricted stock units
|
2025-09-30 |
| 2025-08-12 | 5627.52 | 未披露 | 定期报告 | 2025-08-05 |
| 2025-08-12 | 5618.73 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock upon the vesting of restricted stock units
|
2025-06-30 |
| 2025-05-13 | 5590.06 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock upon the vesting of restricted stock units and performance stock units
|
2025-03-31 |
| 2025-03-27 | 5590.06 | 未披露 | 定期报告 | 2025-03-21 |
| 2025-03-27 | 5459.35 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock upon the vesting of restricted stock units and performance stock units
|
2024-12-31 |
| 2024-11-14 | 5451.82 | 未披露 | 定期报告 | 2024-11-06 |
| 2024-11-14 | 5431.44 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock upon the vesting of restricted stock units and performance stock units
|
2024-09-30 |
| 2024-08-05 | 5404.91 | 未披露 | 定期报告 | 2024-08-01 |
| 2024-08-05 | 5400.91 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock upon the vesting of restricted stock units
|
2024-06-30 |
| 2024-05-15 | 5398.66 | 未披露 | 定期报告 | 2024-05-06 |
| 2024-04-16 | 5389.29 | 未披露 | 定期报告 | 2024-04-05 |
| 2024-05-15 | 5386.91 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Issuance of common stock upon the vesting of restricted stock units and performance stock units
|
2024-03-31 |
| 2024-03-13 | 5386.91 | 未披露 | 定期报告 | 2024-03-08 |
| 2024-03-13 | 5299.97 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of common stock, net of issuance costs
Issuance of common stock upon the vesting of restricted stock units and performance stock units
|
2023-12-31 |
| 2023-11-13 | 5299.93 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock upon the vesting of restricted stock units and performance stock units
Issuance of common stock, net of issuance costs
|
2023-09-30 |
| 2023-09-01 | 5271.63 | 未披露 | 定期报告 | 2023-08-11 |
| 2023-08-10 | 5269.63 | 未披露 | 定期报告 | 2023-08-07 |
| 2023-03-30 | 5257.18 | 未披露 | 定期报告 | 2023-03-01 |
| 2023-03-30 | 5245.62 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock under GSK Share Purchase Agreement, net of discount of $1.3 million
Issuance of common stock upon the exercise of stock options
Issuance of common stock upon the vesting of RSUs
Issuance of common stock, net of issuance costs
Conversion of convertible preferred stock to common stock
|
2022-12-31 |
| 2022-11-14 | 5177.61 | 未披露 | 定期报告 | 2022-11-10 |
| 2022-11-14 | 4285.66 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the vesting of RSUs
Issuance of common stock, net of issuance costs
|
2022-09-30 |
| 2022-08-10 | 3506.75 | 227.52 |
更多>>
From March 31, 2022 to June 30, 2022
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
|
2022-06-30 |
| 2022-05-16 | 3282.15 | 未披露 | 定期报告 | 2022-05-12 |
| 2022-05-16 | 3275.56 | 321.82 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
|
2022-03-31 |
| 2022-03-31 | 3275.56 | 未披露 | 定期报告 | 2022-03-25 |
| 2022-03-31 | 3239.37 | 321.82 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
Issuance of common stock under Pfizer Purchase Agreement, net of premium of $12.5 million and net of financing costs of $0.2 million
Conversion of convertible preferred stock to common stock
|
2021-12-31 |
| 2021-11-10 | 3232.36 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-10 | 3222.04 | 321.82 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
Issuance of common stock under Pfizer Purchase Agreement, net of financing costs of $0.1 million
|
2021-09-30 |
| 2021-08-05 | 3214.68 | 未披露 | 定期报告 | 2021-07-29 |
| 2021-08-05 | 2969.91 | 321.82 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock upon the exercise of stock options
|
2021-06-30 |
| 2021-07-06 | 2969.91 | 未披露 | 定期报告 | 2021-06-24 |
| 2021-05-06 | 2966.52 | 未披露 | 定期报告 | 2021-04-29 |
| 2021-05-06 | 2966.39 | 321.82 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of financing costs of $130 and net of issuance costs
Conversion of convertible preferred stock to common stock
|
2021-03-31 |
| 2021-03-11 | 2950.43 | 321.82 | 定期报告 | 2021-03-05 |
| 2021-03-11 | 2926.02 | 321.83 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of offering costs of $731 and net of issuance costs
Issuance of Series C preferred stock, net of offering costs of $41
Issuance of Series D preferred stock, net of offering costs of $181
Conversion of convertible preferred stock to common stock
|
2020-12-31 |
| 2020-11-13 | 2719.70 | 322.00 | 定期报告 | 2020-11-06 |
| 2020-11-05 | 2718.75 | 未披露 | 定期报告 | 2020-10-29 |
| 2020-11-05 | 2597.01 | 322.00 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of Series D preferred stock, net of offering costs of $186
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of offering costs of $280 and net of issuance costs
|
2020-09-30 |
| 2020-09-30 | 2597.01 | 未披露 | 定期报告 | 2020-09-15 |
| 2020-09-30 | 2118.37 | 未披露 | 定期报告 | 2020-09-01 |
| 2020-08-06 | 2115.25 | 未披露 | 定期报告 | 2020-07-30 |
| 2020-08-06 | 2101.41 | 0.50 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
|
2020-06-30 |
| 2020-05-08 | 2059.53 | 未披露 | 定期报告 | 2020-05-01 |
| 2020-05-08 | 2032.83 | 0.50 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of Series C preferred stock, net of offering costs of $41
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of offering costs of $462
|
2020-03-31 |
| 2020-03-16 | 2032.83 | 未披露 | 定期报告 | 2020-03-09 |
| 2020-02-11 | 1928.21 | 0.27 | 定期报告 | 2020-02-10 |
| 2020-03-16 | 1919.07 | 0.27 |
更多>>
From December 31, 2018 to December 31, 2019
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs of $474
|
2019-12-31 |
| 2019-11-04 | 1912.81 | 未披露 | 定期报告 | 2019-10-31 |
| 2019-11-04 | 1866.30 | 0.27 |
更多>>
From June 30, 2019 to September 30, 2019
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
|
2019-09-30 |
| 2019-08-08 | 1865.62 | 未披露 | 定期报告 | 2019-08-05 |
| 2019-08-08 | 1865.04 | 0.27 |
更多>>
From March 31, 2019 to June 30, 2019
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
|
2019-06-30 |
| 2019-06-14 | 1780.10 | 未披露 | 定期报告 | 2019-06-14 |
| 2019-05-09 | 1752.38 | 未披露 | 定期报告 | 2019-05-06 |
| 2019-04-26 | 1745.57 | 未披露 | 定期报告 | 2019-04-15 |
| 2019-04-26 | 1742.29 | 未披露 | 定期报告 | 2019-04-08 |
| 2019-05-09 | 1733.51 | 0.32 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
|
2019-03-31 |
| 2019-03-14 | 1721.60 | 未披露 | 定期报告 | 2019-03-08 |
| 2019-03-14 | 1720.60 | 0.32 |
更多>>
From December 31, 2017 to December 31, 2018
Issuance of common and Series A preferred stock in public offering, net of issuance costs of $996
Issuance of Series B preferred stock in exchange for common stock
Issuance of common stock upon the exercise of stock options
|
2018-12-31 |
| 2018-12-03 | 1720.60 | 未披露 | 定期报告 | 2018-11-30 |
| 2018-11-08 | 1818.75 | 未披露 | 定期报告 | 2018-11-05 |
| 2018-11-08 | 1818.25 | 未披露 | 定期报告 | 2018-09-30 |
| 2018-08-09 | 1816.84 | 未披露 | 定期报告 | 2018-08-06 |
| 2018-07-11 | 1437.78 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-10 | 1437.78 | 未披露 | 定期报告 | 2018-05-07 |
| 2018-04-02 | 1436.92 | 未披露 |
更多>>
From December 31, 2016 to November 30, 2017
Exchange of units in Spero Therapeutics, LLC for shares in Spero Therapeutics, Inc. on a one-for-one basis
Issuance of common stock, conversion of preferred stock to common stock
Issuance of common stock, initial public offering net of issuance costs of $3,574
|
2017-11-30 |
| 2017-11-02 | 1389.77 | 未披露 |
更多>>
1.Common stock offered by us 5,500,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 8,397,684 shares of our common stock outstanding as of September 30, 2017
3.a one-for-6.0774 reverse stock split of our common stock effected on October 20, 2017
|
2017-11-02 |
| 2017-10-23 | 839.77 | 未披露 |
更多>>
a one-for-6.0774 reverse stock split of our common stock effected on October 20, 2017
|
2017-10-20 |
| 2017-10-06 | 5103.61 | 未披露 | 定期报告 | 2017-08-31 |
From June 30, 2025 to September 30, 2025
Issuance of common stock upon the vesting of restricted stock units
From March 31, 2025 to June 30, 2025
Issuance of common stock upon the vesting of restricted stock units
From December 31, 2024 to March 31, 2025
Issuance of common stock upon the vesting of restricted stock units and performance stock units
From December 31, 2023 to December 31, 2024
Issuance of common stock upon the vesting of restricted stock units and performance stock units
From June 30, 2024 to September 30, 2024
Issuance of common stock upon the vesting of restricted stock units and performance stock units
From March 31, 2024 to June 30, 2024
Issuance of common stock upon the vesting of restricted stock units
From December 31, 2023 to March 31, 2024
Issuance of common stock upon the vesting of restricted stock units and performance stock units
From December 31, 2022 to December 31, 2023
Issuance of common stock, net of issuance costs
Issuance of common stock upon the vesting of restricted stock units and performance stock units
From June 30, 2023 to September 30, 2023
Issuance of common stock upon the vesting of restricted stock units and performance stock units
Issuance of common stock, net of issuance costs
From December 31, 2021 to December 31, 2022
Issuance of common stock under GSK Share Purchase Agreement, net of discount of $1.3 million
Issuance of common stock upon the exercise of stock options
Issuance of common stock upon the vesting of RSUs
Issuance of common stock, net of issuance costs
Conversion of convertible preferred stock to common stock
From June 30, 2022 to September 30, 2022
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the vesting of RSUs
Issuance of common stock, net of issuance costs
From March 31, 2022 to June 30, 2022
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
From December 31, 2021 to March 31, 2022
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
From December 31, 2020 to December 31, 2021
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
Issuance of common stock under Pfizer Purchase Agreement, net of premium of $12.5 million and net of financing costs of $0.2 million
Conversion of convertible preferred stock to common stock
From June 30, 2021 to September 30, 2021
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
Issuance of common stock under Pfizer Purchase Agreement, net of financing costs of $0.1 million
From March 31, 2021 to June 30, 2021
Issuance of common stock upon the exercise of stock options
From December 31, 2020 to March 31, 2021
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of financing costs of $130 and net of issuance costs
Conversion of convertible preferred stock to common stock
From December 31, 2019 to December 31, 2020
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of offering costs of $731 and net of issuance costs
Issuance of Series C preferred stock, net of offering costs of $41
Issuance of Series D preferred stock, net of offering costs of $181
Conversion of convertible preferred stock to common stock
From June 30, 2020 to September 30, 2020
Issuance of Series D preferred stock, net of offering costs of $186
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of offering costs of $280 and net of issuance costs
From March 31, 2020 to June 30, 2020
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
From December 31, 2019 to March 31, 2020
Issuance of Series C preferred stock, net of offering costs of $41
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of offering costs of $462
From December 31, 2018 to December 31, 2019
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs of $474
From June 30, 2019 to September 30, 2019
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
From March 31, 2019 to June 30, 2019
Conversion of convertible preferred stock to common stock
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
From December 31, 2018 to March 31, 2019
Issuance of common stock upon the exercise of stock options
Issuance of common stock, net of issuance costs
From December 31, 2017 to December 31, 2018
Issuance of common and Series A preferred stock in public offering, net of issuance costs of $996
Issuance of Series B preferred stock in exchange for common stock
Issuance of common stock upon the exercise of stock options
From December 31, 2016 to November 30, 2017
Exchange of units in Spero Therapeutics, LLC for shares in Spero Therapeutics, Inc. on a one-for-one basis
Issuance of common stock, conversion of preferred stock to common stock
Issuance of common stock, initial public offering net of issuance costs of $3,574
1.Common stock offered by us 5,500,000 shares
2.The number of shares of our common stock to be outstanding after this offering is based on 8,397,684 shares of our common stock outstanding as of September 30, 2017
3.a one-for-6.0774 reverse stock split of our common stock effected on October 20, 2017
a one-for-6.0774 reverse stock split of our common stock effected on October 20, 2017